Amiodarone-induced thyrotoxicosis types 1 and 2: features of clinical manifestations
- Authors: Davydov D.V.1,2, Chernavsky S.V.1,3, Borisov A.G.1,3, Stremoukhov A.A.3, Dorokhina A.V.1, Artyushkevich O.V.1, Kudentsova L.A.1
-
Affiliations:
- The N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defense of the Russian Federation
- Peoples’ Friendship University of Russia
- Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
- Issue: Vol 343, No 11 (2022)
- Pages: 43-46
- Section: Treatment and prophylactic issues
- URL: https://journals.eco-vector.com/0026-9050/article/view/629740
- DOI: https://doi.org/10.52424/00269050_2022_343_11_43
- ID: 629740
Cite item
Open Access
Access granted
Subscription Access
Abstract
Long-term use of amiodarone sometimes contributes to the development of amiodarone-associated thyrotoxicosis. Allocate 1 and 2 types of this thyroidopathy. According to our study, amiodarone-induced thyrotoxicosis is detected in 57.9% of cases. Its type 1 is most often diagnosed, which often develops in patients with overweight, and is also characterized by more pronounced complaints, a significant clinical picture, and significant morphological and functional changes in the thyroid gland. In patients with type 2 amiodarone-induced thyrotoxicosis, there was a shorter period from the start of taking the drug to the development of clinical manifestations of thyroidopathy, laboratory changes in basal metabolism, as well as manifestations of damage to the cardiovascular system, were less pronounced.
About the authors
D. V. Davydov
The N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defense of the Russian Federation; Peoples’ Friendship University of Russia
Email: chernavskijsv@mail.ru
профессор, полковник медицинской службы
Russian Federation, Moscow; MoscowS. V. Chernavsky
The N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defense of the Russian Federation; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Author for correspondence.
Email: chernavskijsv@mail.ru
доктор медицинских наук, подполковник медицинской службы запаса
Russian Federation, Moscow; MoscowA. G. Borisov
The N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defense of the Russian Federation; Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Email: chernavskijsv@mail.ru
кандидат медицинских наук, полковник медицинской службы запаса
Russian Federation, Moscow; MoscowA. A. Stremoukhov
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation
Email: chernavskijsv@mail.ru
профессор
Russian Federation, MoscowA. V. Dorokhina
The N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: chernavskijsv@mail.ru
Russian Federation, Moscow
O. V. Artyushkevich
The N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: chernavskijsv@mail.ru
Russian Federation, Moscow
L. A. Kudentsova
The N.N.Burdenko Main Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: chernavskijsv@mail.ru
Russian Federation, Moscow
References
- Адашева Т.В., Демичева О.Ю. Кордарон и тиреоидная патология. Мифы и реальность // Мед. вестн. – 2013. – № 17. – С. 12–13.
- Гринева Е.Н., Цой У.А., Каронова Т.Л. и др. Проект федеральных клинических рекомендаций по диагностике и лечению амиодарон-индуцированной дисфункции щитовидной железы // Клин. эксперимент. тиреоидология. – 2020. – Т. 16, № 20. – С. 12–24.
- Крюков Е.В., Потехин Н.П., Фурсов А.Н. и др. Алгоритм ведения пациентов, получающих амиодарон, в зависимости от функционального состояния щитовидной железы // Клин. мед. – 2017. – Т. 95, № 10. – С. 901–904.
- Сметнев А.С., Гроссу А.А., Шевченко Н.М. Диагностика и лечение нарушений ритма сердца. – Кишинев: Штиинца, 1990. – 325 с.
- Igonin V.A., Proskurin M.V., Serebrennikov V.N. Amiodarone-associated thyrotoxicosis: the complexity of diagnosis and treatment // Klin. tireoidologiya. – 2004. – Vol. 2, N 4. – P. 53–55.
- Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system // N. Engl. J. Med. – 2001. – Vol. 344, N 7. – P. 501–509.
- Ursella S., Testa A., Mazzone M., Gentiloni Silveri N. Amiodaroneinduced thyroid dysfunction in clinical practice // Eur. Rev. Med. Pharmacol. Sci. – 2000. – Vol. 10, N 5. – Р. 269–278.
Supplementary files
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).